Navigation Links
Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology
Date:12/9/2008

al Targets of Proteasome Inhibitors Bortezomib and Carfilzomib (Abstract #2657) and The Selective Proteasome Inhibitor Carfilzomib is Well Tolerated in Experimental Animals with Dose Intensive Administration (Abstract #2765).

Carfilzomib acts by inhibiting the proteasome with a high degree of selectivity and is structurally and mechanistically distinct from bortezomib. Preclinical studies designed to assess and compare the off-target activity of bortezomib and carfilzomib indicate that carfilzomib has minimal activity on proteases other than the proteasome. In contrast, bortezomib targets several serine proteases including Cathepsin G, an enzyme whose inhibition may play a role in neuropathic pain. Proteolix researchers believe that these observations may translate into a different and possibly superior safety profile for carfilzomib as compared to bortezomib. In support of this notion, chronic administration of carfilzomib is well tolerated in rats and monkeys with no signs of the significant behavioral and histological neurotoxicities that have been described for bortezomib.

About Multiple Myeloma

According to the American Cancer Society, in 2008, approximately 19,900 new cases of multiple myeloma will be diagnosed in the United States. Newly diagnosed patients have treatment options that include combination chemotherapeutic agents and stem cell transplantation. While many patients respond to treatment, most eventually relapse and require subsequent treatment. Few patients are ultimately cured of their disease.

About Carfilzomib

Carfilzomib is the first in a new class of highly specific proteasome inhibitors. Carfilzomib produces specific and sustained inhibition of the proteasome, leading to apoptosis in cancer cells with minimal off-target effects. In Phase 1 and Phase 2 clinical trials, carfilzomib has demonstrated single-agent activity in hematologic and solid
'/>"/>

SOURCE Proteolix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Proteolixs Carfilzomib Receives Orphan Drug Designation for Treatment of Multiple Myeloma
3. Proteolix Raises $79 Million in Series C Financing
4. Proteolix Presents Preclinical Data for Oral Proteasome Inhibitor PR-047 at the 50th Annual Meeting of the American Society of Hematology
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
7. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
8. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
9. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
10. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today ... September 30, 2014.  Biorem,s complete 2014 third quarter financial statements and ... Financial Summary:Three-months ended September 30, , Nine-months ended ... , 2014 , 2013 , 2014 ... 5,281 , 6,715 , 14,476 Gross profit ...
(Date:11/18/2014)... RPS Diagnostics (RPS®) – a ... announces its third annual partnership of the Centers ... About Antibiotics Week from November 17-23. , Get ... designed to highlight the coordinated efforts of CDC, ... for-profit partners to provide education about the importance ...
(Date:11/18/2014)... Urdorf, Switzerland (PRWEB) November 17, 2014 ... range of processes across the pharmaceutical, chemical, and food ... is it so important, and how do pH sensors ... measurement to assist those in process industries with these ... description of pH measurement in the process industries. The ...
(Date:11/18/2014)... (PRWEB) November 18, 2014 Alanda ... and Transparency Reporting solutions, announced today that a ... using its Consummate Providerâ„¢ solution in both the ... a Global, SaaS based, Data Quality remediation portal, ... their third party Providers improve their ability to ...
Breaking Biology Technology:Biorem Reports Third Quarter Results 2Biorem Reports Third Quarter Results 3RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 2RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 3pH Guide from METTLER TOLEDO Explains Measurement, Theory and Practice of pH Applications 2Alanda Software Completes Successful Implementation of Global Data Quality & Vendor Management Solution for Top Tier Global Biopharmaceutical Company 2
... Ontario, Nov. 6 Helix BioPharma Corp. (TSX, FSE: "HBP" ... and chief operating officer, will present at Merriman Curhan Ford,s ... PM at the Sofitel Hotel in New York City. ... product development programs L-DOS47 and Topical Interferon Alpha-2b. The ...
... - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the ... study of intravenous REOLYSIN(R) in patients with sarcomas metastatic ... 15th Annual Connective Tissue Oncology Society Meeting held in ... poster presentation, entitled "A Phase II Study of Intravenous ...
... The endangered black-footed ferrets inhabit prairie dog towns in the ... The prairie dogs are very susceptible to plague ... U.S. Fish & Wildlife Service (FWS) has implemented a ferret ... their formerly native habitat. Unfortunately, plague can sweep through ...
Cached Biology Technology:Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th 2Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th 3Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 3Colorado Companies Team Up With U.S. Fish & Wildlife Service to Protect Black-Footed Ferret 2
(Date:11/7/2014)... BURBANK, Calif. , Nov. 7, 2014  In conjunction ... Burbank Police Departments, The Community Foundation of the ... BURBANK DNA JUSTICE PROJECT," a $250,000 initiative to ... successful initial phase. In its first six months of existence, ... desperately needed evidence support for local law enforcement. ...
(Date:11/6/2014)... Insilico Medicine, Inc, a Baltimore-based bioinformatics company focused ... announced a research collaboration with the international leader ... (OTC: CSBR). , "There are many companies utilizing ... Oncology,s TumorGraft technology is unique in a way ... generating vast amounts of valuable data. Our bioinformatic ...
(Date:11/4/2014)... In nature, the right amount of death at the ... density, according to new research that could help in ... wildlife stocks. , In a paper in the journal ... University researcher and European colleagues conclude that the kind ... a loss of individuals, or mortality, depends on the ...
Breaking Biology News(10 mins):Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2When less is more: Death in moderation boosts population density in nature 2
... Stephen Moose has developed a corn plant with enormous potential ... silage, Moose said, due to a greater number of leaves ... energy crop. The gene known as Glossy 15 was ... waxy coating that acts like a sun screen for the ...
... for its health benefits. But now scientists have ... produce medicines for several autoimmune and inflammatory diseases, ... open access journal BMC Biotechnology . ... research organizations have participated in the study as ...
... knows, children love sweet-tasting foods. Now, new research ... indicates that this heightened liking for sweetness has a ... rate. "The relationship between sweet preference and growth ... demands increase. Children are programmed to like sweet ...
Cached Biology News:Doubling a gene in corn results in giant biomass 2Tobacco makes medicine 2Liking sweets makes sense for kids 2
Kit containing MACS equipment and reagents for immunopurification of proteins....
... LCMSsolution software offers an intuitive, ... instrument control, diverse data handling, ... requirements. Comprehensive functions include data ... data management in both standalone ...
... a modern flow cytometer, a scientist can ... labeled with fluorescent probes. However, the emission ... cell labeling are broader than the light ... filters. Thus, the fluorescence signal of a ...
... Sigmas FLAG Immunoprecipitation kit allows a ... of an active FLAG-tagged protein. The ... gel, which is a highly specific ... resin. The use of affinity resin ...
Biology Products: